Merck Partner Joins Forces With Emergent Bio To Increase Access To Ebola Treatment
February 2, 2024
CNBC
Emergent BioSolutions Inc (NYSE: EBS ) has agreed to create a collaboration with Ridgeback Biotherapeutics to expand the availability of Ebanga (Ansuvimab-zykl).
FDA approved Ebanga in December 2020 for Ebola.
Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga in the U.S. ... Full story available on Benzinga.com
SweepCast
Simplest Unusual Options Activity Platform for traders. SweepCast can be used for swing or day traders who are looking to get insights on where Smart money is flowing, sign up today.